Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer

被引:20
|
作者
Sun, Xuezheng [1 ]
Hoadley, Katherine A. [2 ,3 ]
Kim, William Y. [2 ,3 ,4 ,5 ]
Furberg, Helena [6 ]
Olshan, Andrew F. [1 ,2 ]
Troester, Melissa A. [1 ,2 ]
机构
[1] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Suite 32,CVS Plaza,137 East Franklin St,CB 8050, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
[4] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA
[5] Univ N Carolina, Dept Urol, Chapel Hill, NC USA
[6] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
关键词
Muscle-invasive bladder cancer; Molecular subtype; Age; Obesity; Smoking; LUMINAL SUBTYPES; BASAL; RISK; ASSOCIATION; PROGNOSIS; SURVIVAL; PATTERNS; STAGE; GRADE;
D O I
10.1007/s10552-017-0885-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Heterogeneity of muscle-invasive bladder cancer (MIBC) has been characterized using whole-genome mRNA expression data, showing distinct molecular and clinicopathological characteristics by subtypes. However, associations between risk factors and molecular subtypes have not been reported. Methods Four previously published schemes were used to categorize molecular subtypes in 372 MIBC patients from the Cancer Genome Atlas (TCGA). Data on gene expression (RNA-seq), demographic, and clinicopathological characteristics were retrieved through TCGA data portal. Polytomous logistic regression was used to estimate the associations of subtypes by different schemes with age at diagnosis, obesity, and smoking. Results While some quantitative variation was evident, distinct molecular subtype schemes showed considerable consistency in the association with the risk factors. Generally, compared to patients with luminal-like tumors, patients with basal-like subtypes were more likely to be older (OR75 + yrs vs. < 60 years range = 1.32-2.89), obese (ORobese vs. normal range = 1.30-3.05), and to start smoking at early age (OR < 18 years vs. 25+ years range = 1.11-4.57). Conclusions Different molecular subtypes of MIBC may have distinct risk profiles. Large population-based studies with detailed information on bladder cancer risk factors are needed to further define etiologic heterogeneity for bladder cancer.
引用
收藏
页码:539 / 544
页数:6
相关论文
共 50 条
  • [31] The management of muscle-invasive bladder cancer
    Albertsen, Peter C.
    BJU INTERNATIONAL, 2021, 128 (03) : 290 - +
  • [32] Management of muscle-invasive bladder cancer
    Moon, Andrew
    Van der Voet, Hans
    Cresswell, Jo
    TRENDS IN UROLOGY & MENS HEALTH, 2015, 6 (06) : 7 - 11
  • [33] Management of muscle-invasive bladder cancer
    Mueller, J.
    Schrader, A. J.
    Schrader, M.
    Schnoeller, T.
    Jentzmik, F.
    MINERVA UROLOGICA E NEFROLOGICA, 2013, 65 (04) : 235 - 248
  • [34] Chemotherapy for Muscle-Invasive Bladder Cancer
    Trenta, Patrizia
    Calabro, Fabio
    Cerbone, Linda
    Sternberg, Cora N.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (01) : 1 - 14
  • [35] Treatment of muscle-invasive bladder cancer
    Sherif, Amir
    Jonsson, Martin N.
    Wiklund, N. Peter
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (09) : 1279 - 1283
  • [36] Molecular Subtypes of Non-muscle Invasive Bladder Cancer
    Lerner, Seth P.
    Robertson, A. Gordon
    CANCER CELL, 2016, 30 (01) : 1 - 3
  • [37] Response to neoadjuvant chemotherapy according to molecular subtypes in muscle-invasive bladder carcinoma.
    Pinto, Alvaro
    Trilla-Fuertes, Lucia
    Pedregosa-Barbas, Jorge
    Garcia-Fernandez, Eugenia
    Wisultschew-Puigdellivol, Alma L.
    Zambrana, Francisco
    Martinez, Imanol
    Gajate, Pablo
    Dittmann, Antje
    Lopez Vacas, Rocio
    Kunz, Laura
    Rubio, Gustavo
    Nieto-Torrero, Sandra
    Lalanda-Delgado, Pedro
    Pertejo, Ana
    Saiz, Ana
    Pilar Gonzalez-Peramato, Maria
    Angel Fresno-Vara, Juan
    Gamez-Pozo, Angelo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] DIAGNOSIS TO CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER: HOW LONG IS SAFE?
    Umbreit, Eric
    Shimko, Mark
    Kim, Simon
    Tarrell, Robert
    Tollefson, Matthew
    Boorjian, Stephen
    Frank, Igor
    JOURNAL OF UROLOGY, 2012, 187 (04): : E643 - E643
  • [39] Intratumoral heterogeneity of molecular subtypes in muscle-invasive bladder cancer An extensive multi-regional immunohistochemical analysis
    Schallenberg, S.
    Dragomir, M.
    Anders, P.
    Ebner, B.
    Volz, Y.
    Eismann, L.
    Rodler, S.
    Casuscelli, J.
    Buchner, A.
    Klauschen, F.
    Stief, C.
    Horst, D.
    Schulz, G. B.
    EUROPEAN UROLOGY, 2023, 83
  • [40] Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer-A Narrative Review
    Sjodahl, Gottfrid
    Abrahamsson, Johan
    Bernardo, Carina
    Eriksson, Pontus
    Hoglund, Mattias
    Liedberg, Fredrik
    CANCERS, 2022, 14 (07)